Magda Melchert
Overview
Explore the profile of Magda Melchert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Griffin P, Komrokji R, de Castro C, Rizzieri D, Melchert M, List A, et al.
Am J Hematol
. 2015 Jun;
90(9):796-9.
PMID: 26089240
Older patients with acute myeloid leukemia (AML) have poor outcomes, with median durations of complete remission lasting less than 1 year. Increased toxicity in older patients limits the delivery of...
2.
Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, et al.
Blood
. 2009 Apr;
113(26):6533-40.
PMID: 19398716
Phase 1 testing of ezatiostat, a glutathione S-transferase P1-1 inhibitor, for the treatment of myelodysplastic syndrome was conducted in a multidose-escalation study. Patients received 10 dose levels (200, 400, 1000,...
3.
Melchert M, List A
Semin Hematol
. 2008 Jan;
45(1):31-8.
PMID: 18179967
Therapeutic alternatives for patients with myelodysplastic syndrome (MDS) have expanded in recent years but remain limited. While agents approved by the US Food and Drug Administration (FDA), including azacitidine, decitabine,...
4.
Melchert M, List A
Hematology Am Soc Hematol Educ Program
. 2007 Nov;
:398-404.
PMID: 18024657
Strategies for the management of anemia in patients with myelodysplastic syndrome (MDS) have evolved following the U.S. Food and Drug Administration (FDA) approval of three new therapeutics from one of...
5.
Melchert M, List A
Int J Biochem Cell Biol
. 2007 Mar;
39(7-8):1489-99.
PMID: 17369076
Over the past 50 years, thalidomide has been a target of active investigation in both malignant and inflammatory conditions. Although initially developed for its sedative properties, decades of investigation have...
6.
Melchert M, Kale V, List A
Curr Opin Hematol
. 2007 Jan;
14(2):123-9.
PMID: 17255789
Purpose Of Review: The aim of this article is to discuss the relevant pathobiologic effects of lenalidomide and the most recent clinical evidence to support its use in patients with...
7.
Melchert M
Oncology (Williston Park)
. 2006 Dec;
20(13):1674-82.
PMID: 17175744
Acute myeloid leukemia (AML) is a disease of the elderly, with the majority of patients diagnosed in their 6th and 7th decade of life. Older patients with AML are less...